Slu-Pp-332

Direct Summary: What is SLU-PP-332?

SLU-PP-332 is a novel synthetic small-molecule pan-agonist that directly targets and activates all three isoforms of the estrogen-related receptor family: ERRα, ERRβ, and ERRγ. In preclinical laboratory models, SLU-PP-332 is investigated for its capacity to stimulate mitochondrial biogenesis, enhance cellular energy expenditure, and promote oxidative muscle fiber phenotype transformation without activating classical nuclear estrogen receptors (ERα or ERβ).

As an essential tool compound in metabolic disease modeling, SLU-PP-332 allows investigators to isolate the downstream transcriptional cascades controlled by nuclear receptors of the ERR superfamily. Researchers interested in evaluating this compound can inspect high-purity analytical batches via SLU-PP-332 research capsules synthesized under rigorous quality controls.

Molecular Identification and Nuclear Receptor Target Profile

Estrogen-related receptors (ERRs) belong to the NR3B subgroup of the nuclear receptor superfamily. Despite structural homology to classical estrogen receptors, ERRs do not bind natural endogenous estrogens such as 17β-estradiol. Instead, they act as orphan nuclear receptors that serve as primary transcriptional regulators of cellular energy homeostasis, electron transport chain gene expression, and mitochondrial mass.

SLU-PP-332 was engineered to overcome the selectivity limitations of legacy ERR ligands. Early synthetic compounds demonstrated partial isoform selectivity or off-target activity against classical estrogen receptors. Structural characterization indicates that SLU-PP-332 occupies the ligand-binding domain (LBD) of ERRα, ERRβ, and ERRγ with high affinity, stabilizing an active conformation that facilitates coactivator recruitment—specifically peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α).

By functioning as a potent pan-agonist, SLU-PP-332 provides researchers with a comprehensive molecular instrument to study maximal ERR-mediated transcriptional activation across diverse tissue models, including skeletal muscle, cardiac tissue, and hepatocytes.

Mechanism of Action: Transcriptional Cascades and PGC-1α Interaction

The primary mechanism of SLU-PP-332 involves binding to the orphan nuclear receptor LBD, inducing a conformational shift that enhances recruitment of the transcriptional coactivator PGC-1α. The PGC-1α/ERR regulatory axis is a fundamental master switch for mitochondrial respiration, driving the transcription of nuclear-encoded mitochondrial genes (NEMGs).

In vitro data indicate that exposure to SLU-PP-332 upregulates expression of core components within the mitochondrial electron transport chain (Complexes I, II, III, IV, and ATP Synthase). Additionally, ERRα activation by SLU-PP-332 stimulates the expression of enzymes integral to fatty acid beta-oxidation, such as carnitine palmitoyltransferase 1A (CPT1A) and medium-chain acyl-CoA dehydrogenase (MCAD).

Importantly, because SLU-PP-332 exhibits negligible cross-reactivity with canonical estrogen receptors ERα (NR3A1) and ERβ (NR3A2), preclinical assays can measure pure metabolic and mitochondrial responses without confounding estrogenic transcriptomic signatures or hormonal signaling events.

Preclinical Findings: Mitochondrial Biogenesis & Energy Expenditure

In animal models of metabolic stress and exercise physiology, administration of SLU-PP-332 has demonstrated profound effects on physiological endurance and cellular bioenergetics. Mouse models evaluated in published literature showed a significant shift toward oxidative muscle remodeling, marked by an increased proportion of Type I (slow-twitch) endurance fibers relative to Type II (fast-twitch glycolytic) fibers.

Preclinical studies suggest that rodent models treated with SLU-PP-332 exhibit elevated baseline oxygen consumption rates (VO2) and increased basal metabolic expenditure without hyperphagia or alterations in caloric intake. These physiological shifts correlate with enhanced running endurance on treadmill assays and increased resistance to metabolic fatigue during forced exertion protocols.

Furthermore, in models of diet-induced obesity, ERR pan-activation via SLU-PP-332 led to reduced accumulation of ectopic lipid droplets in skeletal muscle and liver tissues. The observed clearance of intracellular lipids is attributed to elevated mitochondrial density and accelerated oxidative burning of long-chain fatty acids.

Comparative Analysis: SLU-PP-332 vs. Related Metabolic Research Compounds

To understand the distinct mechanism of SLU-PP-332, it is useful to compare its molecular pathway against other leading compounds investigated in cellular metabolism and mitochondrial biology. Research laboratories frequently assess multiple classes of bioenergetic modulators in parallel across our broader preclinical research library.

While SLU-PP-332 operates via direct pan-activation of nuclear ERR receptors, mitochondrial-derived peptides like MOTS-c research peptide function primarily by modulating the folate cycle and activating AMP-activated protein kinase (AMPK) in the cytoplasm. Conversely, non-peptide small molecules such as the GW-501516 PPARδ agonist target the peroxisome proliferator-activated receptor delta, which drives lipid oxidation through a distinct nuclear receptor subclass.

Additionally, intracellular enzyme inhibitors like the 5-Amino-1MQ target profile act on nicotinamide N-methyltransferase (NNMT) to elevate intracellular NAD+ levels rather than acting directly as nuclear receptor transcription factors. Combining these complementary pathways in distinct experimental cohorts allows researchers to map intersecting nodes in cellular energy regulation.

In Vitro Assays and Preclinical Experimental Frameworks

In vitro investigation of SLU-PP-332 typically utilizes primary skeletal myotubes, C2C12 cell lines, or isolated cardiomyocyte cultures. Standard assay protocols evaluate extracellular acidification rate (ECAR) alongside oxygen consumption rate (OCR) using extracellular flux analyzers to measure real-time mitochondrial bioenergetics.

Researchers analyzing gene expression downstream of SLU-PP-332 exposure utilize quantitative real-time PCR (qRT-PCR) and Western blotting to quantify levels of mitochondrial transcription factor A (TFAM), cytochrome c, and PGC-1α protein expression. Fluorescent microscopic imaging using MitoTracker dyes is routinely employed to confirm physical expansions in mitochondrial network volume and cristae density following compound exposure.

For laboratories establishing standardized in vitro or in vivo dosing protocols, sourcing verified SLU-PP-332 reference compounds ensures that observed alterations in cellular respiration are directly attributable to pure molecule interaction rather than chemical impurities.

Handling, Solubility, and Storage Protocols for Laboratory Use

Proper handling and storage parameters are critical to maintaining the chemical integrity and bioactivity of SLU-PP-332 in laboratory settings. In solid powder or encapsulated formulation, SLU-PP-332 should be preserved in a desiccated environment at -20°C for long-term storage, protected from direct ultraviolet light and humidity.

For solution preparation in analytical and cellular assays, SLU-PP-332 exhibits limited solubility in aqueous buffers but dissolves readily in organic solvents such as dimethyl sulfoxide (DMSO) and ethanol. Stock solutions prepared in high-purity DMSO can be aliquoted and stored at -80°C to prevent freeze-thaw degradation cycles.

When preparing working concentrations for cell culture media, working dilutions should maintain final organic solvent concentrations below 0.1% (v/v) to avoid vehicle-induced cytotoxicity. Researchers should consult batch-specific certificates of analysis for exact molecular weight calculations and solubility thresholds prior to assay execution.

Quality Verification: Analytical Standards & PX1 Specifications

In high-throughput metabolic research, chemical purity and batch consistency are paramount. Low-grade research chemicals containing residual synthetic intermediates or heavy metal contamination can induce off-target cellular toxicity, yielding false-positive or irreproducible experimental outcomes.

PX1 Research ensures that every batch of SLU-PP-332 undergoes exhaustive analytical validation prior to laboratory distribution. Quality control protocols include Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity standards exceeding 98.0%, alongside Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular mass structure.

Additionally, all lots are subjected to Chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm sub-threshold bacterial endotoxin levels. Manufactured within GMP-compliant, ISO 17025 accredited facilities located exclusively in the United States, PX1 provides fully traceable lot-specific Certificates of Analysis (COAs) for every compound across our complete research peptide catalog.

Institutional Procurement and Supply Chain Integrity

Academic institutions, biotechnology organizations, and contract research organizations (CROs) require absolute supply chain transparency when procuring specialized research compounds. PX1 Research maintains centralized inventory facilities in California and Arizona, enabling same-day dispatch for orders placed Monday through Friday.

For high-volume study protocols requiring customized batch sizing, continuous lot consistency, or formal documentation for institutional oversight, researchers can establish specialized institutional accounts through our bulk laboratory research portal. All shipments are packed in temperature-controlled, secure packaging to maintain structural stability throughout transit.